The preeclampsia screening strategies at 11 to 13 weeks yielded similar “screen-positive” rates (of ≈10%) and detection rates for term preeclampsia that were lower with NICE (32.3%) than with the competing-risks model using PAPP-A (41.1%) or PlGF (42.0%; Table 2). This evidence concerns the gene PAPPA and preeclampsia.